Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 |
| |
Authors: | Toogood Peter L Harvey Patricia J Repine Joseph T Sheehan Derek J VanderWel Scott N Zhou Hairong Keller Paul R McNamara Dennis J Sherry Debra Zhu Tong Brodfuehrer Joanne Choi Chung Barvian Mark R Fry David W |
| |
Affiliation: | Medicinal Chemistry, Cancer Pharmacology, and Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA. Peter.toogood2@pfizer.com |
| |
Abstract: | A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|